DrugVision.AI is a service platform from the University of Antwerp and Antwerp University Hospital that brings together an in-house patient-derived organoid biobank, advanced robotic screening, and proprietary image and data analysis to translate complex screening data into meaningful biological insights that accelerate translational drug discovery and precision medicine.

This screening platform offers a pan-cancer tumor organoid biobank together with a robotic phenotypic screening platform that enables high-throughput assessment of repurposed drugs, both as monotherapies and in combination. In addition, by integrating phenotypic screening readouts with baseline omics data, DrugVision.AI provides opportunities to identify predictive biomarkers and improve patient stratification.